生物信息学研究波尔特佐米布耐药性相关蛋白质和地幔细胞淋巴瘤中的信号通路
Linyi Zheng1, Qian Shen2, Guanghong Fang3
1Department of Hematology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
Translational cancer research
|October 21, 2024
概括
这项研究确定了Midkine (MDK) 作为一个关键基因,在地幔细胞淋巴瘤 (MCL) 中对博特佐米布抗性. 升高的MDK血清水平表明耐药性,为向治疗提供了潜在的潜力.
科学领域:
- 基因组学和生物信息学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 覆盖细胞淋巴瘤 (MCL) 中的博特佐米布 (BTZ) 耐药性是一个复杂的问题,涉及多个基因和信号通路.
- 了解BTZ耐药性的分子机制对于开发MCL有效的治疗策略至关重要.
研究的目的:
- 使用生物信息学识别和分析与地细胞淋巴瘤中博特佐米布耐药性相关的差异表达基因 (DEGs).
- 研究关键鉴定基因和相关信号通路在BTZ抵抗机制中的作用.
主要方法:
- 利用基因表达综合 (GEO) 数据集 (GSE20915,GSE51371) 来识别BTZ抗性MCL中的上调 DEG.
- 进行了基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 路径分析,并构建了一个蛋白质-蛋白质相互作用 (PPI) 网络.
- 使用ELISA验证的关键基因表达在40名MCL患者的血清样本中,按治疗反应分类.
主要成果:
- 在两个与MCL中BTZ抗性相关的GEO数据集之间确定了11个常见的上调DEG.
- 对KEGG通路的分析显示了细胞周期,p53,IL-17和NF-κB信号通路的丰富.
- 一项PPI网络分析强调CDKN1A,CDKN1C,MDK和TNFAIP3作为关键候选基因,MDK被确定为主要基因. 与敏感患者相比,BTZ耐药的MCL患者的血清MDK水平显著更高.
结论:
- 鉴定Midkine (MDK) 作为BTZ耐药性的关键基因,为MCL治疗失败的分子基础提供了新的见解.
- 这些发现为探索MDK向疗法以克服地幔细胞淋巴瘤中博特佐米布耐药性的理论基础.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K


